Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis

被引:14
|
作者
Simbrunner, Benedikt [1 ,2 ,3 ,4 ,5 ]
Hartl, Lukas [1 ,2 ]
Jachs, Mathias [1 ,2 ]
Bauer, David J. M. [1 ,2 ]
Scheiner, Bernhard [1 ,2 ]
Hofer, Benedikt Silvester [1 ,2 ,3 ]
Staettermayer, Albert Friedrich [1 ,2 ]
Marculescu, Rodrig [6 ]
Trauner, Michael [1 ]
Mandorfer, Mattias [1 ,2 ]
Reiberger, Thomas [1 ,2 ,3 ,4 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria
[3] Med Univ Vienna, Christian Doppler Lab Portal Hypertens & Liver Fib, Vienna, Austria
[4] Ludwig Boltzmann Inst Rare & Undiagnosed Dis LBI R, Vienna, Austria
[5] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[6] Med Univ Vienna, Dept Lab Med, Vienna, Austria
关键词
ACLD; Portal hypertension; Gut-liver axis; Immune dysfunction; ASCITIC FLUID; DECOMPENSATED CIRRHOSIS; BACTERIAL TRANSLOCATION; COMPLEMENT-SYSTEM; B-CELLS; LIVER; SERUM; INFLAMMATION; ACTIVATION; IGG;
D O I
10.1016/j.jhepr.2023.100712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cirrhosis-associated immune dysfunction (CAID) affects both innate and adaptive immunity. This study investigated the complement system, immunoglobulins, and acute-phase proteins and their prognostic relevance in patients with advanced chronic liver disease (ACLD).Methods: Patients with ACLD (hepatic venous pressure gradient [HVPG] >-6 mmHg) but without acute decompensation/in-fections were characterised by HVPG and by clinical EASL stages: compensated (cACLD; S0-2) vs. decompensated ACLD (dACLD) with previous variceal bleeding (S3), non-bleeding decompensation (S4), or further decompensation (S5). Com-plement factors (C3c, C4, CH50), immunoglobulins (IgA, IgM, IgG, IgG1-4), acute-phase proteins and systemic inflammation biomarkers (white blood cells, C-reactive protein, IL-6, procalcitonin) were measured.Results: A total of 245 patients (median model for end-stage liver disease score: 11 [9-15], median HVPG: 17 [12-21] mmHg) were included with 150 (61%) presenting dACLD. Complement levels and activity significantly decreased in dACLD substages S4 and S5 (p <0.001). Total IgA/IgM/IgG and IgG1-4 subtype levels increased in patients with dACLD (all p <0.05). Complement and immunoglobulin levels correlated negatively and positively, respectively, with systemic inflammation (all p <0.05). High IgG-1 (adjusted hazard ratio per 100 mg/dl: 1.12, 1.04-1.19, p = 0.002) and IL-6 (adjusted hazard ratio: 1.03, 1.00-1.05, p = 0.023) levels predicted the development of infections during follow-up. High IgA (stratified by median; log-rank p <0.001), high IgG1 (log-rank p = 0.043) and low C3c (log-rank p = 0.003) indicated a higher risk of first/further decompensation or liver-related death (composite endpoint). Next to HVPG and IL-6, low C3c (adjusted hazard ratio per mg/dl: 0.99, 0.97-0.99, p = 0.040) remained independently associated with the composite endpoint on multivariate Cox regression analysis.Conclusions: Complement levels and immunoglobulins may serve as surrogates of cirrhosis-associated immune dysfunction and associate with cirrhosis severity and systemic inflammation. Low complement C3c predicted decompensation and liver -related death, whereas high IgG-1 indicated an increased risk for infections.Impact and Implications: Patients with cirrhosis are at increased risk for infections, which worsen their prognosis. We found a significant dysregulation of several essential components of the immune system that was linked to disease severity and indicated a risk for infections and other complications. Simple blood tests identify patients at particularly high risk, who may be candidates for preventive measures.Clinical Trials Registration: This study is registered at ClinicalTrials.gov (NCT03267615).& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Periphery and brain, innate and adaptive immunity in Parkinson's disease
    Harms, Ashley S.
    Ferreira, Sara A.
    Romero-Ramos, Marina
    ACTA NEUROPATHOLOGICA, 2021, 141 (04) : 527 - 545
  • [42] HOST GENETICS OF ADAPTIVE AND INNATE IMMUNITY IN INFLAMMATORY BOWEL DISEASE
    Pappas, Derek J.
    Fear, Anna Lisa
    Mack, Steven J.
    Haritunians, Talin
    McGovern, Dermot P.
    Trachtenberg, Elizabeth A.
    Erlich, Henry A.
    HUMAN IMMUNOLOGY, 2017, 78 : 67 - 67
  • [43] Langerhans cells in cutaneous infections: Cellular bridges between innate and adaptive immunity
    von Stebut, E
    Udey, MC
    CURRENT PROBLEMS IN DERMATOLOGY-US, 2001, 13 (03): : 167 - 172
  • [44] Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure
    Rueschenbaum, Sabrina
    Ciesek, Sandra
    Queck, Alexander
    Widera, Marek
    Schwarzkopf, Katharina
    Bruene, Bernhard
    Welsch, Christoph
    Wedemeyer, Heiner
    Zeuzem, Stefan
    Weigert, Andreas
    Lange, Christian M.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [45] Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease
    Bedsaul, Jacquelyn R.
    Carter, Nicole M.
    Deibel, Katelynn E.
    Hutcherson, Shelby M.
    Jones, Tyler A.
    Wang, Zhaoquan
    Yang, Chao
    Yang, Yong-Kang
    Pomerantz, Joel L.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [46] Role of innate immunity and systemic inflammation in cystic fibrosis disease progression
    Purushothaman, Anand Kumar
    Nelson, Everette Jacob Remington
    HELIYON, 2023, 9 (07)
  • [47] Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19
    Janssen, Nico A. F.
    Grondman, Inge
    de Nooijer, Aline H.
    Boahen, Collins K.
    Koeken, Valerie A. C. M.
    Matzaraki, Vasiliki
    Kumar, Vinod
    He, Xuehui
    Kox, Matthijs
    Koenen, Hans J. P. M.
    Smeets, Ruben L.
    Joosten, Irma
    Brueggemann, Roger J. M.
    Kouijzer, Ilse J. E.
    van der Hoeven, Hans G.
    Schouten, Jeroen A.
    Frenzel, Tim
    Reijers, Monique H. E.
    Hoefsloot, Wouter
    Dofferhoff, Anton S. M.
    van Apeldoorn, Marjan J.
    Blaauw, Marc J. T.
    Veerman, Karin
    Maas, Coen
    Schoneveld, Arjan H.
    Hoefer, Imo E.
    Derde, Lennie P. G.
    van Deuren, Marcel
    van der Meer, Jos W. M.
    van Crevel, Reinout
    Giamarellos-Bourboulis, Evangelos J.
    Joosten, Leo A. B.
    van den Heuvel, Michel M.
    Hoogerwerf, Jacobien
    de Mast, Quirijn
    Pickkers, Peter
    Netea, Mihai G.
    van de Veerdonk, Frank L.
    JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (08): : 1322 - 1333
  • [48] Initial and innate responses to viral infections - pattern setting in immunity or disease
    Biron, CA
    CURRENT OPINION IN MICROBIOLOGY, 1999, 2 (04) : 374 - 381
  • [49] Amyotrophic lateral sclerosis biomarkers may predict disease progression
    Su, X. W.
    Simmons, Z.
    Mitchell, R. M.
    Kong, L.
    Stephens, H. E.
    Connor, J. R.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2014, 4 (01) : 6 - 6
  • [50] Multiple biomarkers predict disease severity, progression and mortality in COPD
    Rachel L. Zemans
    Sean Jacobson
    Jason Keene
    Katerina Kechris
    Bruce E. Miller
    Ruth Tal-Singer
    Russell P. Bowler
    Respiratory Research, 18